January 23, 2007 – Coley Pharma axed its hepatitis C program, after Actilon failed to outperform existing drugs; the data safety committee advised EntreMed to continue its Phase II trial of MKC-1 for breast cancer; Medarex and Compugen will collaborate to develop monoclonal antibodies to fight oncological and autoimmune diseases; Pharmion submitted Thalidomide for approval in Europe; Novavax said its virus-like particle vaccines were effective against two strains of avian flu; Neurocrine will re-submit an application for approval of its sedative indiplon before the end of Q2; Akorn released positive data of a Phase III trial of ocular anesthetic Akten; Shire will out-license the North American rights for an HIV compound to Avexa; and Accuray, Synta and Optimer all set terms for their IPOs. The Centient Biotech 200™ dropped 23 points to 4076, a loss of .57%. More details...
